Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2703-2707

  Hochster, Howard ^a   Chachoua, Abraham ^a   Speyer, James ^a   Escalon, Juliette ^a   Zeleniuch Jacquotte, Anne ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROBABILITY; REMISSION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROBABILITY; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0043132277     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.071     Document Type: Article

References (24)

1. Kidani Y, Noji M, Tashiro T: Antitumor activity of platinum(II) complexes of 1, 2-diamino-cyclohexane isomers. Gann 71:637-643, 1980
2. Tashiro T, Kawada Y, Sakurai Y, et al: Antitumor activity of a new platinum complex, oxalate (trans-1-1, 2-diaminocyclohexane)platinum (II): New experimental data. Biomed Pharmacother 43:251-260, 1989
3. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
4. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886, 1996
5. Mathe G, Kidani Y, Segiguchi M, et al: Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43:237-250, 1989
6. Mathé G, Kidani Y, Triana K, et al: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP). Biomed Pharmacother 40: 372-376, 1986
7. Caussanel JP, Lévi F, Brienza S, et al: Phase I trial of 5-day continuous venous infusion of Eloxatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 82:1046-1050, 1990
8. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of Eloxatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
9. Lévi F, Misset JL, Brienza D, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and Eloxatin using an ambulatory multichannel programmable pump. Cancer 69:893-900, 1992
10. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in subjects with metastatic colorectal cancer. J Clin Oncol 14:2950-2958, 1996
11. deGramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
12. André T, Bernsmaine MA, Louvet C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999
13. deGramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
14. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
15. Goldberg RM, Morton RF, Sargent DJ, et al. N9741 oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
16. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 21:128a, 2002 (abstr 512)
17. Wolmark N, Colangelo L, Wieand S: National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 28:9-13, 2001 (1 suppl 1)
18. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
19. National Cancer Institute Common Toxicity Criteria. Available at: ctep.cancer.gov/reporting/ctc.html
20. Rothenberg ML, Oza AM, Burger B, et al: Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 22:1011a, 2003
21. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
22. deGramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
23. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol. 20:124a, 2001 (abstr 494)
24. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000